Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diagnosed myeloma patients were given bendamustine plus bortezomib and prednisone in a regimen consisting of one cycle of bortezomib twice weekly for 6 weeks (1.3 mg/m(2) on days 1, 4, 8, 11, 22,...

全面介紹

Na minha lista:
書目詳細資料
發表在:Haematologica
Main Authors: Mateos, María-Victoria, Oriol, Albert, Rosiñol, Laura, de Arriba, Felipe, Puig, Noemí, Martín, Jesús, Martínez-López, Joaquín, Echeveste, María Asunción, Sarrá, Josep, Ocio, Enrique, Ramírez, Gemma, Martínez, Rafael, Palomera, Luis, Payer, Angel, Iglesias, Rebeca, de la Rubia, Javier, Alegre, Adrian, Chinea, Ana Isabel, Bladé, Joan, Lahuerta, Juan José, Miguel, Jesús-F. San
格式: Artigo
語言:Inglês
出版: Ferrata Storti Foundation 2015
主題:
Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004426/
https://ncbi.nlm.nih.gov/pubmed/25911554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.124818
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍